A Comparison of Frailty Assessment Instruments in Different Clinical and Social Care Settings: The Frailtools Project.

Frailty instruments clinical and social settings feasibility intertest agreement prevalence

Journal

Journal of the American Medical Directors Association
ISSN: 1538-9375
Titre abrégé: J Am Med Dir Assoc
Pays: United States
ID NLM: 100893243

Informations de publication

Date de publication:
03 2021
Historique:
received: 22 06 2020
revised: 15 09 2020
accepted: 16 09 2020
pubmed: 10 11 2020
medline: 2 7 2021
entrez: 9 11 2020
Statut: ppublish

Résumé

To determine which of 8 commonly employed frailty assessment tools demonstrate the most appropriate characteristics to be employed in different clinical and social settings. Cross-sectional multicenter European-based study. 1440 patients aged ≥75 years evaluated in geriatric inpatient wards, geriatric outpatient clinics, primary care clinics, and nursing homes. The frailty instruments used were Frailty Phenotype, SHARE-FI, 3-item Frailty Trait Scale (FTS-3), 5-item Frailty Trait Scale (FTS-5), FRAIL, 35-item Frailty Index (FI-35), Gérontopôle Frailty Screening Tool (GFST), and Clinical Frailty Scale (CFS). The settings were geriatrics wards, outpatient clinics, primary care, and nursing homes. Suitability was evaluated by considering the feasibility (patients with the test fully completed), administration time (time spent for administering the test), and interscale agreement (Cohen kappa index among instruments to detect frailty). The prevalence of frailty varied across settings and adopted tests. The scales with the mean highest feasibility were the FRAIL scale (99.4%), SHARE-FI (98.3%), and GFST (95.0%). The mean shortest administration times were obtained with CFS (24 seconds), GFST (72 seconds), and FRAIL scale (90 seconds). The interscale agreement between most of the tests was fair. CFS followed by FTS-5 agreed at least moderately with a greater number of scales overall and in almost all settings. Based on feasibility, time to undertake the tool, and agreement with other scales, different scales would be recommended according to the setting considered. Our findings suggest that most of the tools evaluated are actually assessing different frailty constructs.

Identifiants

pubmed: 33162359
pii: S1525-8610(20)30821-5
doi: 10.1016/j.jamda.2020.09.024
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

607.e7-607.e12

Informations de copyright

Copyright © 2020 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Auteurs

Myriam Oviedo-Briones (M)

Fundación para la Investigación Biomédica del Hospital Universitario de Getafe, Madrid, Spain.

Ángel Rodríguez Laso (ÁR)

Fundación para la Investigación Biomédica del Hospital Universitario de Getafe, Madrid, Spain.

José Antonio Carnicero (JA)

Fundación para la Investigación Biomédica del Hospital Universitario de Getafe, Madrid, Spain.

Matteo Cesari (M)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

Tomasz Grodzicki (T)

Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Cracow, Poland.

Barbara Gryglewska (B)

Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Cracow, Poland.

Alan Sinclair (A)

King's College, London, United Kingdom.

Francesco Landi (F)

Hospital Centro Medicina dell'Invecchiamento, Università Cattolica del Sacro Cuore, Rome, Italy.

Bruno Vellas (B)

Gerontopole, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; INSERM-1027, Université de Toulouse III Paul Sabatier, Toulouse, France.

Marta Checa-López (M)

Geriatrics Service, Hospital Universitario de Getafe, Madrid, Spain.

Leocadio Rodriguez-Mañas (L)

Geriatrics Service, Hospital Universitario de Getafe, Madrid, Spain. Electronic address: leocadio.rodriguez@salud.madrid.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH